Profile

Jean-Philippe COLLET MD, PhD
− Institut de Cardiologie-UMRS 166- Hôpital de la Pitié-Salpêtrière-75013 Paris
− Sorbonne Université
− Phone: 00 331 42162962
− Fax: 00 331 42162931
− E-mail:
− Identifiant RPPS : 10001488013
− CNOM : 7562963
− ADELI : 751639626

Administrative and Academic Appointments
Director of the Interventional Catheterization Laboratory
– Interventional Cardiologist at the Institut de Cardiologie of the Hôpital de la Pitié-Salpêtrière_Sorbonne Université, 75013 Paris.

Director of the Cardiovascular Training Program at Sorbonne Université
– Professor of Cardiology at Sorbonne Université

Director of the Research Unit on Thrombosis, Atherothrombosis and Applied Pharmacology (Team 2; UMRS_1166)
– Main research objectives:
– New models for experimental thrombosis
– Demonstration of the prognostic role of biomarkers
– Comparative evaluation of antithrombotic therapies
– Reassessment of antithrombotic drug regimens (PK and PD models for drug evaluation)
– Phase 1 study for oral antithrombotic treatment
– Core laboratory for angiography and biology
– Randomized trials (www.action-coeur.org).

Senior Researcher at the Academic Research Oranization ACTION (action-coeur.org)
– Founding and senior member

Associate Editor at JACC Intervention since 2018

Certifications and Scientific Societies
− Specialist in cardiology (MD), Université Paris XII
− PhD in Thrombosis, University of Rouen, France
− Member of the French Society of Cardiology
− Member of the European Society of Cardiology (FESC)
− Nucleus Member of the Working Group 18 (Thrombosis)
− Member of EAPCI
− Member of the Clinical Practice Guidelines Committee

Research Activities
Dr Jean-Philippe Collet is a Professor of Cardiology at Pitié-Salpêtrière Hospital (APHP) where he leads the interventional catheterization unit (PCI and TAVI). He is also the director of Cardiovascular Training Program at Sorbonne Université. His main expertise is in the field of thrombosis, the effect of antithrombotic agents and the development of new devices for structural heart intervention. He is a member and a founder of the Academic Research Organization A.C.T.I.O.N (Alliés in Cardiovascular Trials, Initiatives and Organized Networks) (www.action-coeur.org). He has led clinical trials as a principal investigator (AMERICA, DOSAPI, ARCTIC and ATLANTIS). He has several commitments in the ESC. He is a Fellow of the European Society of Cardiology, a member of the nucleus of the WG Thrombosis and a member of the Clinical Practice Guidelines Committee. He has served as the Chair of the EAPCI scientific program for two years and is now co-chairing the upcoming 2020 NSTE-ACS guidelines.

Publications
− Articles: 480
− Book chapters: 45
− Abstracts: 200
− H-index=160
− Score SIGAPS 2014-2019 : 1682

Major publications
1. Collet JP, Zeitouni M, Procopi N, Hulot JS, Silvain J, Kerneis M, Thomas D, Lattuca B, Barthelemy O, Lavie-Badie Y, Esteve JB, Payot L, Brugier D, Lopes I, Diallo A, Vicaut E, Montalescot G; ACTION Study Group. Long-Term Evolution of Premature Coronary Artery Disease. J Am Coll Cardiol. 2019 Oct 15;74(15):1868-1878.
2. Collet JP, Silvain J, Barthélémy O, Rangé G, Cayla G, Van Belle E, Cuisset T, Elhadad S, Schiele F, Lhoest N, Ohlmann P, Carrié D, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Beygui F, Vicaut E, Montalescot G; for the ARCTIC investigators. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 2014 6736(14) : 60612-7.
3. Montalescot G, Rangé G, Silvain J, Bonnet JL, Boueri Z, Barthélémy O, Cayla G, Belle L, Van Belle E, Cuisset T, Elhadad S, Pouillot C, Henry P, Motreff P, Carrié D, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Beygui F, Vicaut E, Collet JP; ARCTIC Investigators. High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study. Circulation. 2014 May 27;129(21):2136-43.
4. Collet JP, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrié D, Boueri Z, Belle L, Van Belle E, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Barthélémy O, Beygui F, Silvain J, M D EV, Montalescot G; the ARCTIC Investigators. Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting. N Engl J Med. 2012; 367(22):2100-9

5. Cayla G, Hulot J-S, O’Connor SA, Pathak A, Scott SA, Gruel Y, Silvain J, Vignalou J-B, Huerre Y, de la Briolle A, Allanic F, Beygui F, Barthélémy O, Montalescot G, Collet J-P. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA. 2011; 306:1765–1774.

6. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009 ;373(9660):309-17.

7. Collet JP, Shuman H, Ledger RE, Lee S, Weisel JW. The elasticity of an individual fibrin fiber in a clot. Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9133-7